Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT7SBF5)

• DTT Name: Cellular tumor antigen p53 (TP53) DTT Info
• Gene Name: TP53

Molecule-Related Drug & Molecule List

17 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Contusugene ladenovec	DMN9ETB	Oral cancer	2B6E	Phase 3	[1]
QPI-1002	DMDU5Y2	Renal transplantation	NE84	Phase 3	[2]
Thymoquinone	DMVDTR2	Polycystic ovarian syndrome	5A80.1	Phase 2/3	[3]
Ad-p53	DMJSWXL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
ALT-801	DM9KL7P	Acute myeloid leukaemia	2A60	Phase 2	[5]
APG-115	DMIFA0L	Prolymphocytic leukaemia	2A82.1	Phase 2	[6]
APR-246	DMNFADH	Ovarian cancer	2C73	Phase 2	[7]
INGN-225	DMF7J6D	Head and neck cancer	2D42	Phase 2	[8]
Kevetrin	DMFO6MH	Ovarian cancer	2C73	Phase 2	[6]
SGT-53	DMLYIPA	Pancreatic cancer	2C10	Phase 2	[9]
ISA-P53-01	DMQ5EYJ	Colorectal cancer	2B91.Z	Phase 1/2	[10]
CGM097	DMTCLM3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
COTI-2	DM6K3JQ	Cervical cancer	2C77.0	Phase 1	[6]
Dendritic cell vaccine	DMURVPF	Head and neck cancer	2D42	Phase 1	[11]
HDM201	DMVRTCW	Haematological malignancy	2B33.Y	Phase 1	[12]
ONYX-015	DMBVZND	Head and neck cancer	2D42	Phase 1	[13]
SAR-405838	DMC1AZP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INGN-234	DMJM38Q	Oral cancer	2B6E	Discontinued in Phase 2	[15]
Pifithrin-alpha	DM63OD7	Toxicity	N.A.	Terminated	[16]
TAR-1	DM197D0	Solid tumour/cancer	2A00-2F9Z	Terminated	[17]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	DMC3PYM	Discovery agent	N.A.	Investigative	[18]
NU-8231	DMEUV5R	Discovery agent	N.A.	Investigative	[19]
NUTLIN-3	DM5KXFI	Discovery agent	N.A.	Investigative	[20]

References

• [1] A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
• [4] Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38.
• [5] Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.
• [8] INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
• [9] Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8.
• [10] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [11] Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41.
• [12] National Cancer Institute Drug Dictionary (drug id 761551).
• [13] Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23.
• [14] SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65.
• [15] Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
• [16] An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77.
• [17] Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
• [18] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [19] Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21.
• [20] Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein intera... J Med Chem. 2009 Nov 26;52(22):7044-53.